Journal
INTERNATIONAL JOURNAL OF CARDIOLOGY
Volume 248, Issue -, Pages 232-238Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.ijcard.2017.08.010
Keywords
Hypertrophic cardiomyopathy; Atrial fibrillation; Anticoagulation
Categories
Funding
- Instituto de Salud Carlos III (ISCIII) [RD012/0042/0001, RD012/0042/0002, RD012/0042/0015, RD012/0042/0044, RD12/0042/0029, RD012/0042/0066, RD12/0042/0069]
- Spanish Ministry of Economy and Competitiveness [SAF2015-71863-REDT]
- Bristol-Myers Squibb/Pfizer through an Investigator Initiated Research Grant [CV185-419]
- Plan Estatal de I + D + I 2013-2016 European Regional Development Fund (FEDER) A way of making Europe
Ask authors/readers for more resources
Background: Chronic anticoagulation with vitamin K antagonists (VKAs) is recommended in patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF). Direct oral anticoagulants (NOACs) are an alternative to VKAs but there are limited data to support their use in HCM. We sought to describe the pattern of use, thromboembolic events, bleeding and quality of life in patients with HCM and AF treated with NOACs. Methods: Data from patients treated with NOACs (n = 99) and VKA (n = 433) at 9 inherited cardiac diseases units were retrospectively collected. Annual rates of embolic events, serious bleeding and death were analysed and compared. Quality of life and treatment satisfaction were evaluated with SF-36 and SAFUCA questionnaires in 80 NOAC-treated and 57 VKA-treated patients. Results: After median follow-up of 63 months (IQR: 26-109), thromboembolic events (TIA/stroke and peripheral embolism) occurred in 10% of patients on oral anticoagulation. Major/clinically relevant bleeding occurred in 3.8% and the global mortality rate was 23.3%. Thromboembolic event rate was 0.62 per 100 patient-years in the NOAC group vs. 1.59 in the VKA group [subhazard ratio (SHR) 0.32;95% CI: 0.04-2.45; p = 0.27]. Major/clinically relevant bleeding occurred in 0.62 per 100 person-years in the NOAC group vs. 0.60 in the VKA group (SHR 1.28;95% CI 0.18-9.30; p = 0.85). Quality of life scores were similar in both groups; however, NOAC-treated patients achieved higher scores in the SAFUCA. Conclusions: HCM patients with AF on NOACs showed similar embolic and bleeding rates to those on VKA. Although quality of life was similar in both groups, the NOAC group reported higher treatment satisfaction. (C) 2017 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available